Lok AS - Search Results

1

Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma.

Singal AG, Mukherjee A, Elmunzer BJ, Higgins PD, Lok AS, Zhu J, Marrero JA, Waljee AK. Singal AG, et al. Among authors: lok as. Am J Gastroenterol. 2013 Nov;108(11):1723-30. doi: 10.1038/ajg.2013.332. Epub 2013 Oct 29. Am J Gastroenterol. 2013. PMID: 24169273 Free PMC article.

2

NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States.

Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. Marrero JA, et al. Among authors: lok as. Hepatology. 2002 Dec;36(6):1349-54. doi: 10.1053/jhep.2002.36939. Hepatology. 2002. PMID: 12447858 Free article.

3

Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.

Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Marrero JA, et al. Among authors: lok as. Hepatology. 2003 May;37(5):1114-21. doi: 10.1053/jhep.2003.50195. Hepatology. 2003. PMID: 12717392

4

Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma.

Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Marrero JA, et al. Among authors: lok as. J Hepatol. 2005 Feb;42(2):218-24. doi: 10.1016/j.jhep.2004.10.005. J Hepatol. 2005. PMID: 15664247

5

Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass.

Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS. Marrero JA, et al. Among authors: lok as. Liver Transpl. 2005 Mar;11(3):281-9. doi: 10.1002/lt.20357. Liver Transpl. 2005. PMID: 15719410 Free article. Clinical Trial.

6

Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort.

Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS. Marrero JA, et al. Among authors: lok as. Hepatology. 2005 Apr;41(4):707-16. doi: 10.1002/hep.20636. Hepatology. 2005. PMID: 15795889 Free article.

7

GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma.

Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA, D'Amelio A, Lok AS, Block TM. Marrero JA, et al. Among authors: lok as. J Hepatol. 2005 Dec;43(6):1007-12. doi: 10.1016/j.jhep.2005.05.028. Epub 2005 Jun 28. J Hepatol. 2005. PMID: 16137783

8

Who decides? Living donor liver transplantation for advanced hepatocellular carcinoma.

Volk ML, Marrero JA, Lok AS, Ubel PA. Volk ML, et al. Among authors: lok as. Transplantation. 2006 Nov 15;82(9):1136-9. doi: 10.1097/01.tp.0000245670.75583.3d. Transplantation. 2006. PMID: 17102762 Review.

9

Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.

Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, Askari F, Sullivan P, Lok AS. Sharma P, et al. Among authors: lok as. Liver Transpl. 2007 Aug;13(8):1100-8. doi: 10.1002/lt.21121. Liver Transpl. 2007. PMID: 17377914 Free article.

10

Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3.

Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Volk ML, et al. Among authors: lok as. Cancer Biomark. 2007;3(2):79-87. doi: 10.3233/cbm-2007-3202. Cancer Biomark. 2007. PMID: 17522429

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

634 results

Search Page

Filters